Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Bioinformatics (Oxford, England)
|
October 14, 2003
Sequence alignment kernel for recognition of promoter regions
Leo Gordon, Alexey Ya Chervonenkis, Alex J Gammerman, et al.
Database : the Journal of Biological Databases and Curation
|
March 17, 2016
ncRNA orthologies in the vertebrate lineage
Miguel Pignatelli, Albert J Vilella, Matthieu Muffato, et al.
Leukemia & Lymphoma
|
August 23, 2006
Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum
Beverly P Nelson, Diana Treaba, Charles Goolsby, et al.
British Journal of Haematology
|
April 4, 2019
Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma
Madelyn Burkart, Michael Schieber, Sanjib Basu, et al.
BMC Bioinformatics
|
May 13, 2010
eHive: an artificial intelligence workflow system for genomic analysis
Jessica Severin, Kathryn Beal, Albert J Vilella, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
September 30, 2004
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
Russell Schilder, Arturo Molina, Nancy Bartlett, et al.
British Journal of Haematology
|
February 10, 2022
Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Ishan Roy, Gordon Smilnak, Madelyn Burkart, et al.
Msphere
|
August 24, 2018
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma
Osman Cen, Karuppiah Kannan, Jessica Huck Sappal, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 19, 2026
Validation and Clinical Meaningfulness of the 18-item National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index (NFLymSI-18) in Patients with Lymphoma
Kimberly A Webster, Anne R Zola, Maria Corona, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499
Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Bioinformatics (Oxford, England)
|
October 14, 2003
Sequence alignment kernel for recognition of promoter regions
Leo Gordon, Alexey Ya Chervonenkis, Alex J Gammerman, et al.
Database : the Journal of Biological Databases and Curation
|
March 17, 2016
ncRNA orthologies in the vertebrate lineage
Miguel Pignatelli, Albert J Vilella, Matthieu Muffato, et al.
Leukemia & Lymphoma
|
August 23, 2006
Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum
Beverly P Nelson, Diana Treaba, Charles Goolsby, et al.
British Journal of Haematology
|
April 4, 2019
Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma
Madelyn Burkart, Michael Schieber, Sanjib Basu, et al.
BMC Bioinformatics
|
May 13, 2010
eHive: an artificial intelligence workflow system for genomic analysis
Jessica Severin, Kathryn Beal, Albert J Vilella, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
September 30, 2004
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
Russell Schilder, Arturo Molina, Nancy Bartlett, et al.
British Journal of Haematology
|
February 10, 2022
Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Ishan Roy, Gordon Smilnak, Madelyn Burkart, et al.
Msphere
|
August 24, 2018
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma
Osman Cen, Karuppiah Kannan, Jessica Huck Sappal, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 19, 2026
Validation and Clinical Meaningfulness of the 18-item National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy (NCCN-FACT) Lymphoma Symptom Index (NFLymSI-18) in Patients with Lymphoma
Kimberly A Webster, Anne R Zola, Maria Corona, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499
Mitchell R Smith, Hailun Li, Leo Gordon, et al.
Page
of 3